» Articles » PMID: 39759558

Can the Reprogrammed Cancer Cells Serve As an Alternative Source of (induced) Cancer Stem Cells?

Overview
Specialty Oncology
Date 2025 Jan 6
PMID 39759558
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cancer stem cells (CSCs) constitute a small and elusive subpopulation of cancer cells within a tumor mass and are characterized by stem cell properties. Reprogrammed CSCs exhibit similar capability to initiate tumor growth, metastasis, and chemo- and radio-resistance and have similar gene profiles to primary CSCs. However, the efficiency of cancer cell reprogramming remained relatively low. There is limited literature available on the reprogramming of lung cancer cells. Hence, in this study we have conducted reprogramming of human lung cancer cells towards more benign type of cells.

Materials And Methods: The reprogramming process was carried out with the use of STEMCCA vector. We have investigated the gene expression profile of induced CSCs (iCSCs) using the microarray technique.

Results: The lung iCSCs demonstrate morphology characteristics of induced pluripotent stem cells (iPSCs) and gene expression profile that significantly differ from cells before reprogramming. We have also presented the elevated level of expression of genes associated with the cancer stemness and thus revealed new interesting CSC-like molecular markers.

Conclusions: These preliminary results demonstrated that the reprogramming process leads to the remarkable changes in cells at the gene level and has potential to be an alternative method of generating CSC-like cells.

References
1.
Niemira M, Collin F, Szalkowska A, Bielska A, Chwialkowska K, Reszec J . Molecular Signature of Subtypes of Non-Small-Cell Lung Cancer by Large-Scale Transcriptional Profiling: Identification of Key Modules and Genes by Weighted Gene Co-Expression Network Analysis (WGCNA). Cancers (Basel). 2019; 12(1). PMC: 7017323. DOI: 10.3390/cancers12010037. View

2.
Mery B, Guy J, Espenel S, Wozny A, Simonet S, Vallard A . Targeting head and neck tumoral stem cells: From biological aspects to therapeutic perspectives. World J Stem Cells. 2016; 8(1):13-21. PMC: 4723718. DOI: 10.4252/wjsc.v8.i1.13. View

3.
Romeo H, Arcos M . Clinical relevance of stem cells in lung cancer. World J Stem Cells. 2023; 15(6):576-588. PMC: 10324501. DOI: 10.4252/wjsc.v15.i6.576. View

4.
Chao M, Gentles A, Chatterjee S, Lan F, Reinisch A, Corces M . Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease. Cell Stem Cell. 2017; 20(3):329-344.e7. PMC: 5508733. DOI: 10.1016/j.stem.2016.11.018. View

5.
Alaswad M . Locally advanced non-small cell lung cancer: current issues and recent trends. Rep Pract Oncol Radiother. 2023; 28(2):286-303. PMC: 10348324. DOI: 10.5603/RPOR.a2023.0019. View